The purpose of this study is to test an experimental drug called RMC-6236. RMC-6236 is an experimental drug, which means that it is not approved by the United States (US) Food and Drug Administration (FDA) or any other health authorities. RMC-6236 is currently being investigated in other ongoing studies in non-small cell lung cancer (NSCLC). If you consent and meet the study requirements, you will be randomly assigned to receive either RMC-6236 or docetaxel.

In this study, we want to see if a new drug called Ziftomenib can help treat or cure Leukemia. We want to find out if it is safe and if it works well for people with this disease.

We're trying to find out if a special gel is safe and easy for people with cervical cancer to use. This is for those who are also getting chemotherapy and radiation. We want to see if the gel does its job well, is quick to use, and helps keep healthy tissues safe.

Have you previously been screened for lung cancer? Or are you currently scheduled for a lung cancer screening? We are looking for Black/African American men and women between the ages of 50-80 to participate in a study about lung cancer. Compensation is provided.

Do you have Acute Myeloid Leukemia (AML) and want to try a new study drug that might help treat your cancer?

Have you been diagnosed with GCB Subtype of Diffuse LargeB-cell Lymphoma (DLBCL)? If so, you may be able to take part in a research study looking at Evaluating the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) Plus R-CHP Versus Polatuzumab Vedotin Plus R-CHP in Treatment-naïve Participants With GCB Subtype of Diffuse Large B-cell Lymphoma (DLBCL

The purpose of this study is to test if BGB-16673 and pirtobrutinib are safe and test how well BGB-16673 compares to pirtobrutinib in participants with previously treated Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL).

If you have Leukemia and are looking for an alternative treatment, you may be eligible to participate in a research study testing a new drug called AUTX-007.

Are you 18 years of age and younger than 75 years old? Do you or do you know someone with Peripheral T-cell Lymphoma? Would you be interested in using your own stem cells versus only using chemotherapy infusions? If you have large cell lymphoma (ALCL) ALK-negative, this study may interest you.

To evaluate the anti-tumor activity of carboplatin + MIRV in newly diagnosed subjects with advanced-stage (≥ 75%, ≥ 2+) serous EOC as measured by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 imaging response.